Comparison of Bleeding Risk Between Rivaroxaban and Apixaban for the Treatment of Acute Venous Thromboembolism

PHASE4Active, not recruitingINTERVENTIONAL
Enrollment

2,760

Participants

Timeline

Start Date

December 13, 2017

Primary Completion Date

April 30, 2025

Study Completion Date

August 31, 2025

Conditions
Venous Thromboembolism
Interventions
DRUG

Apixaban

Refer to Apixaban group

DRUG

Rivaroxaban

Refer to Rivaroxaban group

Trial Locations (19)

200606

The University of Sydney, Darlington

Unknown

University of Calgary, Calgary

Alberta Health Sciences, Edmonton

St. Paul's Hospital, Vancouver

Hamilton General Hospital, Hamilton

Juravinski Hospital, Hamilton

St. Joseph's Healthcare Hamilton, Hamilton

Kingston General Hospital, Kingston

Hôpital Sacré-Coeur de Montréal, Montreal

St. Mary's Hospital, Montreal

CHU de Québec-Université Laval, Québec

University of Sherbrooke, Sherbrooke

The Royal College of Surgeons in Ireland/Mater Misericordiae University Hospital, Dublin

B3H 2Y9

QEII Health Science Centre, Halifax

N6A 5W9

London Health Sciences Center, London

K1H 8L6

The Ottawa Hospital - General Campus, Ottawa

M5G 2C4

UHN - Toronto General Hospital, Toronto

H3T 1E2

Jewish General Hospital, Montreal

H4A 3J1

McGill University Health Center, Montreal

All Listed Sponsors
collaborator

Canadian Venous Thromboembolism Clinical Trials and Outcomes Research (CanVECTOR) Network

NETWORK

collaborator

Canadian Institutes of Health Research (CIHR)

OTHER_GOV

lead

Ottawa Hospital Research Institute

OTHER